NUAK2 acts as a potent YAP/TAZ activator, inhibiting LATS1/2 kinase activity, leading to nuclear accumulation of YAP and ultimately tumorigenesis in liver and breast cancers (Yuan et al, 2018; Gill et al, 2018). Here, LATS1 is linked to breast carcinoma.